Inhibition of lipoxygenase activity: implications for the treatment and chemoprevention of prostate cancer.
Nelson
Mark A
MA
Department of Pathology and Arizona Cancer Center, University of Arizona, Tucson, AZ 85715, USA. mnelson@azcc.arizona.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D008084:Lipoxygenase / Q000378:metabolism*; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*; D008297:Male; D010936:Plant Extracts / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents; D016859:Lipoxygenase Inhibitors; D010936:Plant Extracts; C519312:Zyflamend; D008084:Lipoxygenase